Showing 1 - 15 results of 15 for search 'PHARMACEUTICAL CARE', query time: 0.56s Refine Results
  1. 1
    The cost-effectiveness of different diagnostic options of TB among HIV-infected patients
    by V. E. Shumlyanskaya, A. V. Rudakova
    Published 2014-12-01
    “... through modeling, from the health care system perspective, in cohorts with different CD 4+ counts (<200...”
    Get full text
    Article
  2. 2
    PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY
    by A. V. Rudakova, M. S. Berezhnova
    Published 2015-12-01
    “... of varenicline is extremely high (in the analysis from the perspective of the health care system the cost...”
    Get full text
    Article
  3. 3
    PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
    by A. V. Rudakova
    Published 2015-09-01
    “... of care warfarin and aspirin, novel oral anticoagulants rivaroxaban and dabigatran. At the same time...”
    Get full text
    Article
  4. 4
    ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    by A. V. Rudakova
    Published 2015-09-01
    “... and methods. The analysis was performed with the perspective of the health care budget with 5 year horizon...”
    Get full text
    Article
  5. 5
    Vaccination against Pneumococcal Infections of High-Risk People: Pharmacoeconomic Aspects
    by A. V. Rudakova, S. M. Kharit, Yu. V. Lobzin
    Published 2020-01-01
    “... the position of the health care system. The time horizon is 5 and 15 years. It was assumed that vaccination...”
    Get full text
    Article
  6. 6
    Comparative analysis of laparoscopic and laparotomic panhysterectomy costs in patients with early stage endometrial cancer
    “..., and in-patient care. Indirect costs were based on statistical data on salaries in 2016 and employment...”
    Get full text
    Article
  7. 7
    Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
    by A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
    Published 2014-11-01
    “... that requires significant public health care expenditures.Objective: to evaluate the cost-effectiveness...”
    Get full text
    Article
  8. 8
    Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
    by A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
    Published 2014-11-01
    “...) is a serious problem that requires significant public health care expenditures.</p><p><strong>Objective...”
    Get full text
    Article
  9. 9
    COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION
    by A. V. Rudakova, V. A. Parfenov
    Published 2015-09-01
    “... health care system perspective.Material and methods. This analysis used a Markov model that allowed...”
    Get full text
    Article
  10. 10
    VACCINATION AGAINST PNEUMOCOCCAL INFECTIONS IN RUSSIAN FEDERATION: SOCIAL AND PHARMACOECONOMIC ASPECTS
    “... the position of the health care system.The analysis was carried out for 65-year-old citizens with low (absence...”
    Get full text
    Article
  11. 11
    INFLUENZA VACCINATION OF CHILDREN OF PRESCHOOL AGE IN THE RUSSIAN FEDERATION: COST-EFFECTIVENESS OF QUADRIVALENT VACCINE
    “... was carried out by a modeling method from a health care system and societal perspective taking into account...”
    Get full text
    Article
  12. 12
    Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers
    “... of simeprevir and narlaprevir was conducted from the perspective of the health care system based on QUEST-1...”
    Get full text
    Article
  13. 13
    Сost-effectiveness of the second wave of protease inhibitors in the treatment of chronic hepatitis C (genotype 1) in patients not previously treated with antiviral drugs, and for relapsed disease
    “... of simeprevir and narlaprevir was conducted from the perspective of the health care system and base on QUEST-1...”
    Get full text
    Article
  14. 14
    PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION
    “... is conducted from the perspective of the health care system. The assessment took into account only the cost...”
    Get full text
    Article
  15. 15
    Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment
    by A. V. Rudakova, E. A. Stadnik
    Published 2020-04-01
    “... monotherapy.Materials and methods. Analysis was performed by a simulation method from a position of the health care...”
    Get full text
    Article
Search Tools: Get RSS Feed — Email this Search